Mandatory Convertible Bond 2021/2027
Below you find further information about the issuance of mandatory convertible bonds that was resolved by the Management Board of Epigenomics AG with approval of the Supervisory Board on June 11, 2021.
This website and the information contained therein do not constitute an offer to sell or a solicitation of an offer to buy any securities of Epigenomics AG in the United States of America (“U.S.”) or in any other jurisdiction or to any person if such offer or solicitation is unlawful or not authorized. Users of this website are requested to inform themselves about and to observe any such restrictions. The information set forth on this website must not be distributed in or to the U.S., to “U.S. persons” as defined in Regulation S under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or to publications with a general circulation in the U.S. Each violation of such limitations may constitute a violation of applicable securities laws. The securities of Epigenomics AG (the “Securities”) have not been and will not be registered under the Securities Act and may not be offered or sold in the U.S. unless pursuant to an exemption from registration requirements.
Bondholders shall have the right (the “Conversion Right”) to convert each mandatory convertible bond in its entirety at the conversion price into convertible shares within the first 14 calendar days of each calendar quarter (each, a “conversion period,” as further defined in the terms and conditions of the bonds) beginning on October 1, 2021 (inclusive) and ending on July 15, 2027 (exclusive).
First conversion period: 1 to 14 October 2021
|Publication of Inside Information according to Article 17 MAR / June 11, 2021|
|Publication of Inside Information according to Article 17 MAR / August 20, 2021|
|Corporate News / August 24, 2021|
|Corporate News / September 13, 2021|
|Subscription offer (Please note: Currently there is only a German version available)|
|Terms and Conditions|
|Basic information sheet (German only)|
For further information, please don’t hesitate to contact us:
Frederic Hilke (IR.on AG)
Tel: +49 221 9140-970